|
Pennsylvania
Bextra® attorney
On
April 7, 2005 the FDA announced that it has asked Pfizer, Inc.
to withdraw Bextra from the
market "because the overall risk versus benefit profile for
the drug is unfavorable."
|
Attorney
Information
|
FDA
Information |
| For
a free case evaluation from a Pennsylvania attorney, click here:
lawforum |
Click
here to read the FDA
questions and answers about strengthened warnings on Bextra®
boxes. |
| Munley,
Munley & Cartwright, P.C. is a Pennsylvania law office which
has breaking news and information about this lawsuit |
To
report any unexpected adverse or serious events associated
with the use of Bextra® contact the FDA MedWatch program
on the internet or at 1-800-FDA-1088 |
Speak to your doctor right away
about alternatives to this drug if you are currently using it.
Side Effects
for Bextra or Valdecoxib include the following:
-
Potential
for increased risk of cardiovascular events
-
Gastrointestinal
bleeding
-
Serious
skin reactions, some resulting in death.
Bextra® is
a COX-2 selective agent. It is
prescribed for inflammation and pain from arthritis or menstrual
cramping. Other drugs in this class include Celebrex® and
Vioxx®. Bextra® and Celebrex® are both marketed by
Pharmacia Corporation and Pfizer
and Vioxx® is manufactured by Merck. Doctors switched patients
from Vioxx® to Bextra® when Merck voluntarily removed it from the
market due studies showing an increased risk for heart attack
and stroke.
bextra
site map
Autism
Education Materials!
|
